Botanical and Plant-Derived Drugs: Global Markets

Publication Date	January 2009
Publisher	BCC Research
Product Type	Report
Pages	130
ISBN Number	not applicable
Product Code	BCC00290

Buy this product or for assistance call +44 20 7060 7474

PDF £2,915.00$4849 | €3263

PRINT £2,915.00$4849 | €3263

FAX Order above formats by FAX

Summary

Study Background

Because the use of plant-derived drugs has become so widespread, there is a great need to develop an up-to-date base of market information about these products. More than 2 years have passed since BCC Research published its study of Plant-Derived Drugs: Products, Technology, Applications, which analyzed the key growth areas in plant-derived drugs and developed quantitative market projections.

since then, there have been to our knowledge no broad-based quantitative market analyses that focus specifically on a new class of drugs called botanical drugs that are a subset of plant-derived drugs and formally defined by the U.S. Food and Drug Administration (FDA) in 2004.

Study Goal and Objectives

The present study meets this need by focusing on the global market for plant-derived drugs in light of the most recent available information. in addition to looking at future and current markets for a wide variety of new, reformulated, and established products, the study will analyze technological, environmental, legal/regulatory, and socioeconomic developments that may influence the market for plant-derived drugs.

This report provides an analysis of the emerging botanical drug industry and markets, geographically and by therapeutic area. The future of plant-derived drugs will also be discussed.

More Specific Objectives Are as Follows:

Identify and classify the botanical and plant-derived drugs that have been commercialized to date
Identify and evaluate the impact of factors that will drive future demand for botanical drugs with a focus too on plant-based drugs overall
Forecast the volume and value of shipments of botanical drugs through 2013
Describe botanical drugs that are currently in the clinical testing or approvals stage and assess the probability that they will be commercialized successfully in the next 5 years
Forecast the potential market for these drug candidates, weighted to reflect the estimated probability that they will be commercialized
Identify the leading manufacturers of plant-derived drugs and the firms that may become important players in the next 5 years
Assess the long-term outlook for the plant-derived drugs industry, taking into account market opportunities as well as technological, environmental, legal/regulatory and socioeconomic factors

Intended Audience

The report has been written for the entire pharmaceutical community, but is tailored especially for readers with an interest in the marketing, management, and public policy dimensions of botanical drugs, including readers in the following:

The pharmaceuticals industry, especially companies supplying bulk or formulated plant-derived drugs, or companies that are planning to enter this field
Medical research institutions
International organizations and governmental organizations with relevant responsibilities such as health, drug safety, conservation and the environment, and foreign trade
Investors
The financial and analyst community

Scope of Report

This report is an analytical business tool whose primary purpose is to describe the botanical drug industry with the overall plant-derived drug industry as a backdrop and the global market for these drugs going forward.

for the purposes of this report, botanicals are those drugs that are FDA approved under the botanical drug pathway, while plant-derived drugs are those under the FDA's new classification, which includes both botanicals as well as other approved drugs that contain a mixture of natural plant-derived and synthetic substances.

The study's main focus is on legal, prescription-required therapeutic medicines sold in the open market. The study does not specifically cover herbals generally sold as dietary supplements (I.e., to promote overall "wellness" rather than to address a specific medical condition or symptoms). While there is a substantial market for these products, the medical value of many of these substances has not been demonstrated conclusively.

The Study Also Does Not Cover The following:

Underground or illicit drugs
Home remedies
Tribal medicines
Drugs derived from archaea, bacteria, and fungi (molds and yeasts)
Non-medicinal plant substances such as laxative cellulose and pectin fiber
Intravenously delivered nutrients of plant origin, such as dextrose
Plant-derived substances serving as pharmaceutical excipients, such as starch, methylcellulose, guar gum, vegetable oils, fatty acids, cocoa butter, and candelilla wax
Plant substances serving in cosmetics, toiletries, and personal care products
Microbial fermentation products, even those made with culture media incorporating corn steep liquor, starch, or other plant-derived nutrients
Marine life

The Format of The Study Is Organized around The following Topics:

Major types and applications of botanical drugs with plant-derived drugs as their backdrop
Industry structure
Market size and segmentation, including breakdown of sales by therapeutic area and geographic area
Market drivers
Market projections through 2013
Competition
Observations and conclusions regarding the future of the botanical and plant-derived drug industry

Content

Chapter 1: Introduction
- Study Background
- Study Goal and Objectives
- Intended Audience
- Scope of Report
- Methodology and Information Sources
- Commercial Drugs
  - Developmental Drugs
- Analyst Credentials
- Related BCC Publications
- BCC Online Services
- Disclaimer
Chapter 2: Summary
Chapter3: Overview
- Brief History of Plant-Derived Medicines
- Opportunity Lies beyond What's Known
- Key Drivers
- Key Challenges
- Signs of Industry Investment
  - Botanical Drugs Defined
- Understanding The Regulatory Process
- The First Approved Botanical
- A Growing Pipeline
- Overall Pharma Landscape
  - Major Classes of Plant Drugs
    - Terpenes and Steroids
    - Terpenes
    - Steroids
    - Alkaloids and Glycosides
    - Alkaloids
      - Ergot Alkaloids
      - Morphine Alkaloids
      - Vinca Alkaloids
    - Glycosides
      - Cardiac Glycosides
      - Anthraglycosides
    - Phenols
    - E. Cava Algae
    - Flavonoids
      - Resveratrol
    - Coumarin
    - Catechins
    - Proanthocyanidins
- Intellectual Property
- Production
  - Moving Production Forward
  - Artemisinin: A Case Study
- Supply and Legal Issues
  - Drug Development and Manufacture
Chapter 4: Market Segmentation
- Geographic Segmentation
  - Sales of Plant-Derived Drugs by Region
- Therapeutic Area Segmentation
  - Number of Plant-Derived Drugs by Therapeutic Area
    - Value of Plant-Derived Drugs by Therapeutic Area
Chapter 5: Therapeutic Areas in Detail for Plant-Derived and Botanical Drugs, through 2013
- Hormone Therapy and Metabolism Applications
- Infectious Disease Applications
  - Pain and Central Nervous System Disease Applications
  - Cardiovascular and Metabolic Disease
- Respiratory, Inflammation, and Autoimmune
  - Dermatology Applications
  - Gastrointestinal Applications
  - Oncology Applications
Chapter6: Company Profiles
- Advanced Life Sciences
- Artecef B V
- American Oriental Bioengineering
- Analyticon Discovery Gmbh
- Avesthagen, Ltd
- Bayer Schering
- Bionumerik Pharmaceuticals, Inc
- Bionovo, Inc
  - Boehringer Ingelheim
  - Pharmaton Sa
- Bristol Myers Squibb
- Cardax Pharmaceuticals
- Chong Kun Dang Pharmaceutical Corporation
- Cubist Pharmaceuticals, Inc
- Curapharm, Inc
- Eisai, Inc
- Ekomed, Llc
- Eli Lilly
- Fytokem Products, Inc
- Galapagos Nv
- Glaxosmithkline
- Global Pharmatech, Inc
- Gw Pharmaceuticals, Plc
- Heterogeneity, Llc
- Indena
  - Johnson & Johnson
- Lifepharms, Inc
- Leo Pharma
- Lupin, Ltd
  - Lupin Pharmaceuticals, Inc
- Madaus Gmbh
- Mera Pharmaceuticals, Inc
- Meridian Medical Technologies, Inc
  - King Pharmaceuticals, Inc. (Parent Company)
- Merlion Pharmaceuticals
- Medigene
  - Medigene, Inc
- Merck & Co , Inc
- Microbio
- Napo Pharmaceuticals, Inc
- Neurogesx, Inc
- Novartis International Ag
- Panacos
- Phytomedical Technologies
- Phytomedics, Inc
  - Pfizer
- Polyphenon Pharma
  - Phynova
- Phytoceutica, Inc
- Phytomyco Research Corp
- Phytopharm, Plc
- Piramal Enterprises, Ltd
- Punisyn Pharmaceuticals, Ltd
- Ranbaxy Laboratories, Ltd
- Sanofi-Aventis
- Schwabe Pharmaceuticals
- Sequoia Sciences, Inc
- Sirtris
- Solvay Pharmaceuticals
- Sunten Phytotech Co , Ltd
- Tasly Pharmaceuticals, Inc
- Tcm Biotech International Corp
- Vedic Lifesciences Pvt , Ltd
- Yaupon Therapeutics
- Wyeth Pharmaceuticals
- Zhejiang Kanglaite Group Co, Ltd
- Appendix
List of Summaries
- Summary Table Global Forecast for Botanical* and Plant-Derived Drugs, through 2013 ($ Billions)
- Summary Figure Global Forecast for Botanical* and Plant-Derived Drugs, through 2013 ($ Billions)
List of Tables
- Table 1 Fda Approval Process for New Drugs
- Table 2 Key Dates in Botanical Medicine
- Table 3 Well Known Plant-Derived Drugs
- Table 4 SWOT Analysis on Botanical Drug Development
- Table 5 Key Signs of Investment in Botanical and Other Plant-Derived Drugs
- Table 6 Distinctions among Products That Use Plants Medicinally
- Table 7 Top Pharma Companies by Revenue, 2007 ($ Billions)
- Table 8 Major Producers of Raw Materials for Plant- Based Medicinals
- Table 9 Key Companies with Natural Product Libraries
- Table 10 Plant-Derived Drug Sales Forecast by Region, through 2013 (% Total Sales)
- Table 11 Fda Approved Botanical Drugs Forecast through 2013 (Units)
- Table 12 Relative Values of Fda Approved Botanical Drugs Forecast by Therapuetic Area, through 2013 ($ Millions)
- Table 13 Plant-Derived Hormone Therapy and Metabolism Drugs in Late Stage Development
- Table 14 Plant-Derived Infectious Disease Drugs in Late Stage Development
- Table 15 Brain Disorders That Are Refractory to Small Molecule Drugs
- Table 16 Plant-Derived Pain and CNS Drugs in Late Stage Development
- Table 17 Plant-Derived Cardiovascular and Metabolic Drugs in Late Stage Development
- Table 18 Plant-Derived Respiratory, Inflammation, and Autoimmune Drugs in Late Stage Development
- Table 19 Plant-Derived Dermatology/Wound Care Drugs in Late Stage Development
- Table 20 Plant-Derived Gastrointestinal Drugs in Late Stage* Development
- Table 21 Estimated U S. Cancer Cases, 2007
- Table 22 Plant-Derived Oncology Drugs in Late Stage Development
- Table 23 Botanical Drugs in Late Stage Development with Expected Fda-Approved Commercialization, through 2013*
- Table 24 Medigene Botanical Pipeline
- Table 25 Phynova Pipeline
- Table 26 Suntech Phytotech Pipeline
- Table 27 Plant-Derived Drugs: Their Origin and Actions131
- Table 28 Useful Resources for The Botanical Drug Industry
List of Figures
- Figure 1 Composition of Fda-Approved Natural-Derived Compounds in U S. (2000-2005)* (%)
- Figure 2 Inds in The Fda by Therapeutic Area (Number)
- Figure 3 Geographic Segmentation for Plant-Derived Drugs, 2008 and 2013 (%)
- Figure 4 Composition of Fda Approved Botanical Indication Forecast by Therapeutic Area, 2008 and 2013 (%)*
- Figure 5 Relative Values of Fda Approved Botanical Drugs Forecast by Therapeutic Area, 2008 and 2013 (%)